The Week in Review, which we will post soon, is going to provide news that cancer patients, their parents, their oncologists and investors are anxiously waiting to hear.  

The news is about studies with products demonstrating huge improvements in immunotherapy efficacy in addition to preventing checkpoint inhibitors such as: Opdivo, Keytruda and others, from causing adverse effects, including autoimmune reactions that are serious and sometimes devastating.

In The Week in Review we will name the drugs and the firms that have them in their pipelines and the conducted trials and the entities that conducted . . .